Show simple item record

dc.contributor.authorSowerbutts, Anne Marie; email: annemarie.sowerbutts@manchester.ac.uk
dc.contributor.authorBurden, Sorrel
dc.contributor.authorGriffiths, Jane
dc.contributor.authorAbraham, Arun
dc.contributor.authorFarrer, Kirstine
dc.contributor.authorLeahy, Gavin
dc.contributor.authorTeubner, Antje
dc.contributor.authorCloutier, Anabelle
dc.contributor.authorTwist, Katherine
dc.contributor.authorKelly, Sarah
dc.contributor.authorLal, Simon
dc.date.accessioned2021-08-14T00:45:28Z
dc.date.available2021-08-14T00:45:28Z
dc.date.issued2021-06-22
dc.date.submitted2021-03-22
dc.identifierpubmed: 34330477
dc.identifierpii: S2405-4577(21)00216-3
dc.identifierdoi: 10.1016/j.clnesp.2021.06.005
dc.identifier.citationClinical nutrition ESPEN, volume 44, page 263-269
dc.identifier.urihttp://hdl.handle.net/10034/625579
dc.descriptionFrom PubMed via Jisc Publications Router
dc.descriptionHistory: received 2021-03-22, revised 2021-05-25, accepted 2021-06-03
dc.descriptionPublication status: ppublish
dc.description.abstractPatients with short bowel syndrome and type 3 intestinal failure (SBS-IF) are dependent on parenteral nutrition (PN), a lifesaving treatment but inconvenient and with risks. Glucagon-like peptide 2 analogue (teduglutide) can reduce patients' need for PN. However, it comes with the risk of a number of side effects. This qualitative study investigated patients' decision making process to start teduglutide and how family members contributed to the decision. In-depth semi-structured interviews were conducted with nine participants, six patients with SBS-IF and three family members about the decision to take teduglutide. Interviews were transcribed verbatim and analysed using framework analysis. The prominent motivation for taking teduglutide (Revestive® Takeda Pharmaceuticals Limited) was reducing or stopping PN. Other motivations were to help others by assisting in developing the knowledge base around teduglutide, patients felt that they had nothing to lose by trying the drug and the support of relatives. The reasons patients considered not taking the drug were that they had accepted being on PN, the potential side effects of teduglutide and undergoing extra monitoring. However, the monitoring programme also acted as a motivator providing reassurance that patients would be observed and supported with side effects. Family members were happy to support patients' decision to try teduglutide, although they had more reservations, indicating a higher risk threshold. Patients considered potential benefits of teduglutide outweighed any disadvantages. Relatives, although supportive, had more reservations. [Abstract copyright: Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.]
dc.languageeng
dc.sourceeissn: 2405-4577
dc.subjectShort bowel syndrome
dc.subjectQualitative
dc.subjectPatient experience
dc.subjectParenteral nutrition
dc.subjectGlucagon-like peptide 2
dc.subjectTeduglutide
dc.titleGlucagon-like peptide 2 analogues in the treatment of intestinal failure: A qualitative exploration of the views of patients and their families in decision making.
dc.typearticle
dc.date.updated2021-08-14T00:45:27Z
dc.date.accepted2021-06-03


This item appears in the following Collection(s)

Show simple item record